Sun Pharmaceuticals on Friday reported a consolidated net profit of Rs 2,714 crore for the March-ended quarter, up 22% from Rs 2,150 crore in the year-ago period. The drugmaker also posted a 13% increase in revenue to Rs 14,612 crore in Q4FY26, compared with Rs 12,959 crore in the corresponding quarter of the previous financial year.
However, profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore reported in the October-December quarter of FY26.